KBC Group
NUVB icon

KBC Group’s Nuvation Bio NUVB Stock Holding History

KBC Group’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37K Buy
+8,699
New +$48.5K ﹤0.01% 1748

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

KBC Group's NUVB Position: Q1 2026 in Review

KBC Group opened a new position in Nuvation Bio (NUVB) in Q1 2026: 8,699 shares worth $37K. The stake represents ﹤0.01% of the portfolio and ranks #1748 among its holdings.

231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • KBC Group held 8,699 shares of Nuvation Bio worth $37K as of Q1 2026.
  • Nuvation Bio was a new KBC Group position in Q1 2026.
  • Nuvation Bio made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1748 holding.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.